The HPV testing and Pap test market size was valued at USD 1.67 billion in 2020 and is expected to surpass USD 7.25 billion, expanding at a CAGR of 16.4% during the forecast period, 2021–2028. The growth of the market is attributed to the rising number of cervical cancer screening events and development of several innovative screening devices.
HPV testing and Pap test are primarily used for the detection of cancerous cells in the body. HPV or human papillomavirus consists of a group of more than 150 related viruses and Pap tests are widely used to identify tumor formation and precancers in the cervix. Precancers are mainly caused by HPV and some of the HPV types develops cervical cancer without proper treatment. Some of the most common consequences of the HPV include cancer formation in several body parts such as vagina, vulva, anus, and penis along with some parts of the mouth and throat, and cervix. A Pap test is done for precancerous conditions of vaginal cancer, cervix, and cervical cancer. In the COVID-19 situation impacted by emergency lockdown, the number of cervical cancer screening test globally had decreased to 80% as compared to the previous decline record of 94% in April 25, 2020.
According to the World Health Organization (WHO), approximately 99% cases of cervical cancer are linked with HPV infection. The cervical cancer is common among women above the age of 40 years and is largely diagnosed among women between the ages of 35 to 44 years. The increasing number of awareness events and programs by healthcare organizations such as WHO, CDC, the U.S. Preventive Services Task Force, and National Cervical Cancer Coalition is one of the key aspects for the market growth. In the UK, the Public Health England initiated awareness campaign to increase adoption of the screening tests among women in the country, which plays a crucial role for the rising use of testing procedures in the country.
Market Trends, Drivers, Restraints, and Opportunities
- Rising number of cervical cancer cases worldwide present key factor driving the market growth.
- Increasing governments’ initiatives and policies for public awareness programs especially for women are another major factors for the market expansion.
- High incidence of cervical cancer especially vaginal cancer and increasing demand for innovative screening techniques for the treatment are major factors which are expected to drive the market growth.
- Increasing technology advancement in diagnostic procedures and development of several screening techniques by major players in the market are likely to boost the market.
- The COVID-19 pandemic and its dire consequences have impacted to enormously reduce regular cancer screening tests. This acts as a key restraining factor for the market.
Scope of the Report
The report on the global HPV testing and Pap test market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
HPV Testing and Pap Test Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Test Types (HPV Testing and Pap Test), Applications (Cervical Cancer Screening and Vaginal Cancer Screening), Products (Instruments, Consumables, and Services), Technology (PCR, Immunodiagnostics, and Others), End-users (Hospitals & Clinics, Laboratories, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Abbott Laboratories; Qiagen N.V.; Becton, Dickinson and Company; Quest Diagnostics, Inc.; Hologic, Inc.; F. Hoffmann-La Roche AG; Femasys, Inc.; Arbor Vita Corporation; NURX, Inc.; Seegene, Inc.; Thermo Fisher Scientific, Inc.; and bioMérieux SA
Market Segment Insights
HPV testing segment is expected to grow at a rapid pace
Based on test types, the global HPV testing and Pap test market is bifurcated into HPV testing and Pap test. The HPV testing segment is expected to grow at a rapid pace during the projected period due to rising commercialization of innovative tests related to HPV infection. However, the Pap test segment is anticipated to account for a key share of the market during the forecast period owing to increasing awareness programs by healthcare authorities and rising implementation of policies to adopt mandatory screening of cervical cancer.
Vaginal cancer screening segment is projected to expand at a considerable CAGR
On the basis of applications, the market is bifurcated into cervical cancer screening and vaginal cancer screening. The cervical cancer screening segment is projected to hold a key market share in the coming years owing to higher incidence of cervical cancer and growing public-private initiatives to increase screening of cervical cancer. On the other hand, the vaginal cancer screening segment is anticipated to expand at a considerable CAGR during the forecast period due to high mortality rates of vaginal cancer and demand for screening test.
Consumables segment is expected to expand at a robust growth rate
Based on products, the global HPV testing and Pap test market is divided into instruments, consumables, and services. The services segment is anticipated to constitute a large market share during the projected period due to the increase in number of at-home screening of cervical cancer. On the other hand, the consumables segment is anticipated to expand at a robust growth rate during the forecast period owing to growing activities by key market players through the launch of novel consumables such as assays and kits for more precise HPV and Pap tests.
PCR segment is expected to register a high CAGR
On the basis of technology, the market is divided into PCR, immunodiagnostics, and others. The PCR segment is expected to register a high CAGR during the projected period due to the execution of new rules for utilizing DNA HPV testing methods for accurate and inexpensive treatment. On the other hand, the others segment is projected to account for a major share of the market during the forecast period owing to adoption of cystoscopy and colposcopy techniques cervical cancer screenings and in HPV.
Hospitals & clinics segment is expected to grow at a considerable rate
Based on end-users, the global HPV testing and Pap test market is classified into hospitals & clinics, laboratories, and others. The hospitals & clinics segment is expected to grow at a considerable rate as these institutions provide primary care services for the treatment of all diseases including cervical cancer and HIV. Meanwhile, the others segment is anticipated to expand at a rapid pace during the forecast period due to rise in the number of usage of POC test in-home settings.
North America is anticipated to constitute a key market share
In terms of regions, the global HPV testing and Pap test market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key share of the market during the targeted period owing to increased awareness about early diagnosis of cervical cancer and healthcare remuneration scenarios in the region. On the other hand, the market of Asia Pacific is anticipated to expand at a healthy growth rate during the forecast period due to rising number of cancers and increasing adoption of advanced technology in the region.
Segments Covered in the Report
The global HPV testing and Pap test market has been segmented on the basis of
- Cervical Cancer Screening
- Vaginal Cancer Screening
- Hospitals & Clinics
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Abbott Laboratories
- Qiagen N.V.
- Becton, Dickinson and Company
- Quest Diagnostics, Inc.
- Hologic, Inc.
- F. Hoffmann-La Roche AG
- Femasys, Inc.
- Arbor Vita Corporation
- NURX, Inc.
- Seegene, Inc.
- Thermo Fisher Scientific, Inc.
- BioMérieux SA
Key players competing in the HPV testing and Pap test market are Abbott Laboratories; Qiagen N.V.; Becton, Dickinson and Company; Quest Diagnostics, Inc.; Hologic, Inc.; F. Hoffmann-La Roche AG; Femasys, Inc.; Arbor Vita Corporation; NURX, Inc.; Seegene, Inc.; Thermo Fisher Scientific, Inc.; and bioMérieux SA. Qiagen N.V. developed the QIAscreen HPV PCR Test, in November 2018, which was a molecular diagnostic test used to diagnose HPV.